Home > TAGRISSO® (osimertinib): Patient Support Program Closure

Important Update to the AstraZeneca Oncology Patient Support Program (PSP) for TAGRISSO® (osimertinib) FLAURA2 – Free Drug Component Closure

Dear Health Care Provider,

On July 10th, 2024, AstraZeneca Canada received Notice of Compliance (NOC) for TAGRISSO® in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.

The PSP for TAGRISSO FLAURA2 opened on October 7, 2024, and is providing eligible patients with reimbursement navigation, co-pay assistance, free-drug, pharmacy services, drug distribution, and access to educational resources.

We are pleased to share that AstraZeneca Canada has reached an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of TAGRISSO in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. We are working diligently to finalize Provincial Listing Agreements with every Canadian province and territory, and we will notify you upon listing in your respective province/territory. We are hopeful for timely access for patients and are committed to working with the provincial payers to provide public access for patients as quickly as possible.

We are now writing to remind you that the planned closure of enrollment into the free drug component of the TAGRISSO FLAURA2 PSP is May 15th, 2025.

With the forthcoming closure, AstraZeneca Canada will be discontinuing the free drug component of the PSP for all NEW patients enrolled after May 15th, 2025. Details regarding the refined PSP program are outlined below:

  • All eligible patients enrolled in the free drug component of the PSP on or before May 15th, 2025, will continue to receive free drug through the PSP until disease progression, or provincial coverage, whichever is earlier.
  • After May 15th, 2025, all NEW eligible patients enrolled into the FLAURA2 PSP will still have access to:
    • ✓ Educational resources
    • ✓ Reimbursement navigation
    • ✓ Co-pay assistance
    • X The free-drug component for the TAGRISSO FLAURA2 PSP will no longer be available

If you have any questions, please do not hesitate to contact the Patient Support Program directly at 1-877-280-6208.

Regards,

Your Patient Care Coordinator

AstraZeneca Oncology Patient Support Program